Joseph Pantginis

Kristen Kluska

Chris Howerton

Joe Pantginis

Samuel Slutsky

Thomas Smith

Yatin Suneja

- Celldex reported **positive initial data** from the Phase 1 study of CDX-622, a novel bispecific antibody targeting inflammation and fibrosis.  **[744218_748c4a52d5df4e7fb08cd417b19d15ac_0]** 
- CDX-622 was **well tolerated**, exhibited a good pharmacokinetic profile, and led to **rapid and sustained reductions in serum tryptase**, indicating mast cell inhibition and depletion.  **[744218_748c4a52d5df4e7fb08cd417b19d15ac_0]** 
- The drug demonstrated a **long half-life of approximately 18 days** at 9 mg/kg with no measurable immunogenicity.  **[744218_748c4a52d5df4e7fb08cd417b19d15ac_0]** **[744218_748c4a52d5df4e7fb08cd417b19d15ac_1]** 
- Celldex has progressed the study to test multiple ascending doses and plans to **initiate a Phase 1b study in mild to moderate asthma patients next year**.  **[744218_748c4a52d5df4e7fb08cd417b19d15ac_0]** 
- Data from Part 2 and Part 3 of the Phase 1 study are **expected in Q3 2026**.  **[744218_748c4a52d5df4e7fb08cd417b19d15ac_2]**

Celldex Therapeutics (CLDX)